News Agency
Men's Weekly

Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS mCRC, and HCC neoadjuvant therapy published at ESMO Asia 2023

  • Written by PR Newswire

First-line therapy for gastric cancer and metastatic colorectal cancer, neoadjuvant therapy for hepatocellular carcinoma

HONGKONG, Dec. 5, 2023  /PRNewswire/ -- Akeso (9926.HK) published results from three investigator-initiated trials (IITs) of its bispecific IO drug, cadonilimab (a PD-1/CTLA-4 bispecific antibody), at the 2023 European...

Read more: Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS...

Managing Business Risk Through Content Governance in Headless CMS

As businesses scale their digital presence, content becomes a critical asset that directly impacts reputation, compliance, and operational efficiency. However, without proper governance, content can quickly become a source of risk. Inaccurate information, inconsistent messaging, or non-compliant content can lead... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion